| DOR to Present Live Webcast at New York Society of Security Analysts’ 8th Annual Heathcare Conference |
Print this story |
DOR BioPharma, Inc. (AMEX:DOR) (DOR or the Company), announced today that Gregory J. Davenport, Ph.D., President of DOR’s BioDefense Division, will be presenting at the ...
DOR BioPharma, Inc. (AMEX:DOR) (DOR or the Company), announced today that Gregory J. Davenport, Ph.D., President of DOR’s BioDefense Division, will be presenting at the New York Society of Security Analysts, 8th Annual Healthcare Industry Conference in New York City. Dr. Davenport will be presenting during a special afternoon session focused on the biodefense sector.
Dr. Davenport will be providing an overview of the DOR’s biodefense programs, including an update on the status and anticipated upcoming events relating to DOR’s ricin and botulinum toxin vaccines. Dr. Davenport’s presentation will occur on Wednesday, November 17, 2004, at 3:10pm ET at the Harvard Club, 27 West 44th St, New York, NY 10036.
A simultaneous live webcast of Dr. Davenport’s audio/visual presentation may be accessed through DOR’s website at http://www.dorbiopharma.com by logging onto DOR’s website tomorrow, Wednesday, November 17, 2004 at approximately 3:00pm ET. A replay of the live webcast will be available on DOR’s website for approximately 30 days following the webcast.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of biodefense vaccines and therapeutics for areas of unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin. DOR’s lead therapeutic product, orBec(R) (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal graft vs. host disease (iGvHD), a severe, life-threatening form of gastrointestinal inflammation. As previously announced, DOR completed the treatment phase of its pivotal Phase III clinical trial of orBec(R) and expects to announce top line results of this trial before the end of the year, and pending a positive outcome, filing an NDA for marketing authorization as early as April 2005. orBec(R) has been granted fast track status by the FDA for the treatment of iGVHD. For further information regarding DOR BioPharma, please visit the Company’s website located at http://www.dorbiopharma.com.
This press release contains, and the webcast is expected to contain, forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma’s current expectations about its future results, performance, prospects and opportunities. Where possible, DOR BioPharma has tried to identify these forward-looking statements by using words such as anticipates, believes, intends, or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR BioPharma cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to patent, register or protect its technology from challenge and products from
competition or maintain or expand its license agreements with its current licensors, that it will be able to maintain its listing on the American Stock Exchange, or that its business strategy will be successful. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR BioPharma’s most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.
|
| HSA Resources Bank Launches Health Savings Accounts - Nov 17, 2004 13:37 IST |
|
HSA Resources in association with Stearns Bank N.A. announces the launch of H S A Resources Bank with a user friendly and simplified Health Savings Account (HSA) solution today.
|
| New Natural Health Discovery Protects From Seven Deadly Diseases - Nov 17, 2004 13:25 IST |
|
MonaVie and Acai Berry found to have unprecedented health benefits. If you pay any attention to the latest in health news, you’ve probably heard of free radicals and what they can do to your body. Basically, free radicals cause oxidation of your body’s cells, similar to what happens when metal gets rusty or fruit turns brown as it sits in the open air.
This free radical damage contributes to what many call the seven deadly diseases: heart disease, diabetes, cancer, stroke, arthritis, alzheimer’s, and osteoporosis.
|
| President Bush’s Premier Health Plan Explained - Nov 17, 2004 13:19 IST |
|
President Bush Endorsed, Promoted, and Encouraged people to have Health Savings Accounts. Health Savings Accounts with qualified medical coverage. Its really very simple to understand and quite affordable. http://www.HSAFL.com
Health Coverage: Approved insurance company offers a qualified medical high deductible health plan. For individuals the deductibles are $1000, $1700, or 2600.
|
| Dade Behring and Premier Sign Agreement for Microbiology Instruments, Reagents - Nov 17, 2004 13:10 IST |
|
Dade Behring (NASDAQ:DADE) and Premier announced that they have signed a multi-year agreement in which Premier, one of the largest group purchasing organizations in the United States, has agreed to a three-year contract for Dade Behring’s MicroScan(R) microbiology instruments and reagents. This agreement is in addition to the announcement earlier this year of an agreement between Premier and Dade Behring for Dimension chemistry systems, StreamLab automation systems, Stratus(R) CS, Syva(R) Emit tests and hemostasis tests. Dade Behring is a worldwide leader in the field of diagnostics.
The extension of our microbiology business with Premier reflects the very positive partnership we have developed together through the years, said Jim Reid Anderson, Chairman, President and CEO, Dade Behring. It also ensures that Premier’s members--and their patients--have our commitment to provide them with the best clinical diagnostics to improve the quality of health care.
|
| Light Up My life - Nov 17, 2004 13:9 IST |
|
With the clocks going back, millions of British workers will be heading home this evening in the dark. Depressing? Yes, but there could be a good reason for why we get the winter blues. When Jenny Simmonds had her first bout of SAD 20 years ago, the doctors said it was postnatal depression.
But then her spirits slumped again the following winter. She was depressed two years after the birth, says husband Jon. I’m no doctor, but I thought, ’this isn’t postnatal’. It happened again the next year, and the next. For 10 years we were told it was a chemical imbalance.
|
| EPCglobal US Supports FDA Initiative to Protect U.S. Drug Supply Chain from Counterfeit Drugs - Nov 17, 2004 12:28 IST |
|
Addressing significant challenges facing the health and life sciences industries, such as counterfeiting, the EPCglobal Inc(TM) Healthcare and Life Sciences Business Action Group has made the tracking and tracing of pharmaceutical pedigree a top priority in the development of Electronic Product Code(TM) (EPC) technology.
Today’s announcement by EPCglobal US, an affiliate of EPCglobal serving subscribers in the United States to help foster the adoption of the EPCglobal Network(TM) and leverage radio frequency technology (RFID) in the supply chain, comes on the heels of the U.S. Federal Drug Administration’s (FDA) announcement of a new initiative designed to protect the U.S. drug supply chain from counterfeit products.
|
| Enzon to Present at Credit Suisse First Boston Healthcare Conference - Nov 17, 2004 12:10 IST |
|
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that the company will participate in the Credit Suisse First Boston Healthcare Conference, which is being held November 17-19, 2004 in Phoenix, Arizona. Ken Zuerblis, Enzon’s chief financial officer, will give a 25-minute presentation on Wednesday, November 17, 2004 at 3:30 p.m. MST or 5:30 p.m. EST.
|
| Commercial Viability of Phosphatase Enzyme Class as Therapeutic Targets Analysed - Nov 17, 2004 11:53 IST |
|
Research and Markets (http://www.researchandmarkets.com/reports/c9232) has announced the addition of Phosphatases: Emerging Role in Signal Transduction, Human Therapeutics, & As Drug Targets to their offering.
Recently, several members of the phosphatase drug target class have been identified and classes of compounds have been screened with hits identified.
|
| ``Pass the Potatoes’’ This Holiday Season and Lose Weight - Nov 17, 2004 11:51 IST |
|
This holiday season, passing the potatoes doesn’t have to mean calorie counting and extra hours at the gym. Lately, potatoes have been a casualty in the carb-free, protein-centric diet craze, but recent clinical data shows that harnessing the power inside the potato can actually be a key component in the struggle to lose and manage weight. Video Available
|
| Current uses of Green-Fluorescent Protein in Biopharmaceutical Industry Examined - Nov 17, 2004 11:47 IST |
|
Research and Markets (http://www.researchandmarkets.com/reports/c9202) has announced the addition of A Guide to Green-Fluorescent Protein to their offering.
This resource-oriented practical Guide provides an all encompassing overview of the most important features and technological applications of Green-Fluorescent Protein and its variant forms. It seeks to describe Green-Fluorescent Protein’s usefulness in biomedical programs and applications.
|
| New findings may redirect strategies for treatment of prostate cancer - Nov 17, 2004 11:41 IST |
|
A new research study published in the November issue of Cancer Cell may have important implications for treatment of prostate cancer, the most common malignancy afflicting males in the United States. The research provides significant and somewhat surprising new information about modulation of the androgen receptor (AR), a key determinant of prostate cancer progression and an attractive target for prostate cancer therapies.
|
| Autism may be caused by brain swelling due to immune system reaction - Nov 17, 2004 11:40 IST |
|
Autism could be caused by an immune system reaction which causes the brain to swell, say researchers at John Hopkins University School of Medicine, USA. If this is so, we may one day be able to create a test for autism, and perhaps even develop treatment to prevent it.
|
| Egg donors could be paid £1,000, UK - Nov 17, 2004 11:39 IST |
|
Women who donate their eggs to infertile couples could be paid up to £1,000 under new proposals from the Human Fertilisation and Embryology Authority (HFEA).
Although the sale of gametes is illegal, the EU Tissues and Cells Directive, which comes into force from next April, says donors may receive compensation for the inconvenience of the procedure.
|
| Faith in God is down to your genes, says Researcher - Nov 17, 2004 11:38 IST |
|
Whether or not you are religious and believe in God is down to your genes, says Dean Hamer, National Cancer Institute’s Gene Structure Regulation Unit, USA. He reckons Jesus, Mohammed (the prophet) and Buddha probably carried the ‘God Gene’ in them. Church representatives have criticised Dean Hamer’s findings.
|
| Arthritis patients ’failed’ by NHS, UK - Nov 17, 2004 11:38 IST |
|
The NHS is failing to provide adequate support for those suffering with musculoskeletal conditions (MSCs), according to new research.
A study conducted by the Arthritis and Musculoskeletal Alliance (ARMA) found that many patients are being subjected to poor standards of care and provided with little support to help them deal with their condition.
|
| Charities call for smoking ban - Nov 17, 2004 11:37 IST |
|
The UK’s leading cancer charities are calling on the Government to introduce a full ban on public smoking.
Macmillan Cancer Relief, the Roy Castle Lung Cancer Foundation, the British Lung Foundation and Marie Curie Cancer Care are jointly requesting that England follow the example of Ireland and Scotland and impose an outright smoking ban in enclosed public places such as bars and restaurants.
|
| Reid denies health plans will restrict freedom, UK - Nov 17, 2004 11:36 IST |
|
The Government aims to protect public health but its plans will not restrict people’s freedom of choice, health secretary John Reid has said.
Tomorrow’s White Paper on public health is expected to suggest how to tackle the increasing problems of childhood obesity and smoking-related illnesses.
|
| Inactive form of scatter factor protein found to suppress tumor growth and spread - Nov 17, 2004 11:35 IST |
|
Scatter factor (SF) is a growth factor that controls the proliferation and survival of many tissues by promoting invasive growth in both normal and disease-related biological processes.
Produced in a precursor form, pro-SF must be cleaved in order to activate its receptor, Met tyrosine kinase.
|
| Take the Dust Mite Quiz! - Nov 17, 2004 11:34 IST |
|
To help people learn about and reduce dust mites from their homes, the American Lung Association and ProTeam, maker of high-performance vacuum cleaners, have launched a simple online quiz that will test consumers’ Dust Mite I Q.
With a time limit of 30 seconds per question, visitors quickly choose from multiple-choice answers to questions that test their knowledge about dust mite basics: where they live in your home, what they feed on, how they can affect your breathing, and how to control them. Click here to take the quiz!
|
| MS Patients Benefit from Pumping Iron - Nov 17, 2004 11:34 IST |
|
Researchers in Melbourne, Australia, have found that exercise can have significant benefits for patients with multiple sclerosis (MS), challenging the conventional medical wisdom.
Doctors normally do not recommend that patients with MS do strenuous exercise.
|
|
|
|
|
